Journal article

Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes

Emily J Gianatti, Rudolf Hoermann, Que Lam, Philippe Dupuis, Jeffrey D Zajac, Mathis Grossmann

CLINICAL ENDOCRINOLOGY | WILEY-BLACKWELL | Published : 2016

Abstract

OBJECTIVE: To assess the effect of testosterone treatment on cardiac biomarkers in men with type 2 diabetes (T2D). DESIGN: Randomized double-blind, parallel, placebo-controlled trial. PATIENTS: Men aged 35-70 years with T2D and a total testosterone level ≤12·0 nmol/l (346 ng/dl) at high risk of cardiovascular events, median 10-year United Kingdom Prospective Diabetes Study (UKPDS) coronary heart disease (CHD) risk 21% (IQR 16%, 27%). Eighty-eight participants were randomly assigned to 40 weeks of intramuscular testosterone undecanoate (n = 45) or matching placebo (n = 43). MAIN OUTCOME MEASURES: N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs..

View full abstract

Grants

Awarded by NHMRC


Awarded by CVL Research Grant Pfizer Australia


Funding Acknowledgements

EG was supported by NHMRC Postgraduate Fellowship (#1018196), CVL Research Grant Pfizer Australia (#CR05.09), RACP/Osteoporosis Australia Research Entry Grant and University of Melbourne Postgraduate Scholarship. PD was supported by Bourse du CMDP (Comite des Medecins, Dentistes et Pharmaciens) du CHUQ (Centre Hospitalier Universitaire de Quebec) et de la Fondation du CHUQ - CMDP 2011-2012. MG was supported by an NHMRC Career Development Fellowship (#1024139).